BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 28283298)

  • 1. The Efficacy of Generic Imatinib as First- and Second-line Therapy: 3-Year Follow-up of Patients With Chronic Myeloid Leukemia.
    Islamagic E; Hasic A; Kurtovic S; Suljovic Hadzimesic E; Mehinovic L; Kozaric M; Kurtovic-Kozaric A
    Clin Lymphoma Myeloma Leuk; 2017 Apr; 17(4):238-240. PubMed ID: 28283298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison of the efficacy and safety of Chinese generic imatinib and branded imatinib in patients with chronic myeloid leukemia in consideration of demographic characteristics].
    Dou XL; Yu L; Qin YZ; Shi HX; Lai YY; Hou Y; Huang XJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):924-931. PubMed ID: 31856442
    [No Abstract]   [Full Text] [Related]  

  • 3. Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia.
    Lejniece S; Udre I; Rivkina A
    Exp Oncol; 2017 Jul; 39(2):151-154. PubMed ID: 29483494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generic Imatinib in Chronic Myeloid Leukemia Treatment: Long-Term Follow-up.
    Ćojbašić I; Mačukanović-Golubović L; Vučić M; Ćojbašić Ž
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):e526-e531. PubMed ID: 31239209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec.
    Eskazan AE; Sadri S; Keskin D; Ayer M; Kantarcioglu B; Demirel N; Aydin D; Aydinli F; Yokus O; Ozunal IE; Berk S; Yalniz FF; Elverdi T; Salihoglu A; Ar MC; Ongoren S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):804-811. PubMed ID: 28847475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A comparison of efficacy and safety between Chinese generic imatinib versus branded imatinib in patients with newly-diagnosed chronic myeloid leukemia in the chronic phase: a single-center prospective cohort study].
    Shi HX; Qin YZ; Lai YY; Huang XJ; Jiang Q
    Zhonghua Nei Ke Za Zhi; 2016 Dec; 55(12):922-926. PubMed ID: 27916045
    [No Abstract]   [Full Text] [Related]  

  • 7. Generic Imatinib Therapy Among Jordanians: An Observational Assessment of Efficacy and Safety in Routine Clinical Practice.
    Awidi A; Abbasi S; Alrabi K; Kheirallah KA
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):e55-e61. PubMed ID: 28844599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of generic and original imatinib in the treatment of newly diagnosed patients with chronic myelogenous leukemia in chronic phase: a multicenter retrospective clinical study].
    Jiang H; Zhi LT; Hou M; Wang JX; Wu DP; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2017 Jul; 38(7):566-571. PubMed ID: 28810322
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparable Efficacy and Safety of Generic Imatinib and Branded Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia With a Consideration of Socioeconomic Characteristics: A Retrospective Study From a Single Center.
    Dou X; Qin Y; Lai Y; Shi H; Huang X; Jiang Q
    Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):e304-e315. PubMed ID: 32209331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy.
    Bonifacio M; Scaffidi L; Binotto G; Miggiano MC; Danini M; Minotto C; Griguolo D; Marin L; Frison L; D'Amore F; Basso M; Sartori R; Tinelli M; Stulle M; Fortuna S; Bonalumi A; Bertoldero G; De Biasi E; Ruggeri M; Semenzato G; Fanin R; Pizzolo G; Krampera M; Tiribelli M
    Leuk Res; 2018 Nov; 74():75-79. PubMed ID: 30308414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.
    Shih YT; Cortes JE; Kantarjian HM
    Lancet Haematol; 2019 Aug; 6(8):e398-e408. PubMed ID: 31208943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
    Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
    Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Branded and Generic Imatinib Plasma Concentrations in Patients With Chronic Myelogenous Leukemia: Unicentric Study.
    Ostojic A; Sertic D; Roncevic P; Peric Z; Granic P; Matic N; Basic-Kinda S; Serventi-Seiwerth R; Radman I; Zadro R; Nemet D
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):472-6. PubMed ID: 27245313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs.
    Erçalışkan A; Seyhan Erdoğan D; Eşkazan AE
    Blood Adv; 2021 Sep; 5(17):3344-3353. PubMed ID: 34477815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.
    Padula WV; Larson RA; Dusetzina SB; Apperley JF; Hehlmann R; Baccarani M; Eigendorff E; Guilhot J; Guilhot F; Hehlmann R; Mahon FX; Martinelli G; Mayer J; Müller MC; Niederwieser D; Saussele S; Schiffer CA; Silver RT; Simonsson B; Conti RM
    J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26944912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
    Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
    Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A retrospective analysis of the efficacy and safety of imatinib in children with chronic myeloid leukemia during chronic phase].
    Zhang LQ; Zheng J; Chen ZP; Li SD; Ma J; Wu RH
    Zhonghua Er Ke Za Zhi; 2019 Feb; 57(2):113-117. PubMed ID: 30695885
    [No Abstract]   [Full Text] [Related]  

  • 18. Predictive parameters for imatinib failure in patients with chronic myeloid leukemia.
    Lekovic D; Gotic M; Milic N; Zivojinovic B; Jovanovic J; Colovic N; Milosevic V; Bogdanovic A
    Hematology; 2017 Sep; 22(8):460-466. PubMed ID: 28327053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment status of tyrosine kinase inhibitors in Chinese patients with chronic myeloid leukemia in 2020].
    Wang HF; Zhang YL; Liu XL; Zhu HL; Liang R; Liu BC; Zhou L; Meng L; Li WM; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2021 Jul; 42(7):535-542. PubMed ID: 34455739
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of Deeper Molecular Responses on Outcomes in Chronic Myeloid Leukemia Patients in Chronic Phase Treated With Imatinib Mesylate.
    Kaygusuz Atagunduz I; Toptas T; Deniz R; Kara O; Eser A; Sezgin A; Ozgumus T; Gecgel F; Firatli Tuglular T
    Clin Lymphoma Myeloma Leuk; 2017 Feb; 17(2):120-125. PubMed ID: 28082113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.